We’re proud to announce that IQVIA has been named the winner of the Fierce CRO Award in the category of Innovative Approaches to Patient-Centric Research—a recognition that highlights our commitment to transforming clinical trials through bold innovation and a relentless focus on the patient experience.

Leading the future of clinical research

At IQVIA, we’re not just adapting to the future of clinical research—we’re creating it. Our teams are pioneering new ways to make clinical trials more accessible, patient-centric and effective. From AI-powered recruitment strategies to mobile research units and decentralized clinical trial (DCT) technology integrations, we’re working to improve the trial experience for patients and sites alike.

“This award is a powerful validation of how our teams deliver technology solutions that drive better patient experiences and trial outcomes,” said Susan Hill, Senior Vice President of Product Management, Digital Products & Solutions at IQVIA. “It’s a moment of pride—and a motivator. This award tells us we’re making a meaningful difference with our customers, and it inspires us to keep pushing the boundaries of what’s possible in clinical research.”

What sets IQVIA apart

IQVIA’s recognition is rooted in our ability to integrate cutting-edge technologies with patient-first strategies. With over 500 DCTs conducted and more than 333,000 active participants, we’ve demonstrated how innovation can drive real-world impact. Key differentiators include:

• AI-powered patient relationship manager: Personalizes patient interactions using natural language processing and sentiment analysis.
• eSource and remote monitoring: Enables direct-to-patient data collection and reduces the need for in-person visits.
• IQVIA Connected Intelligence: Combines clinical expertise, global data and advanced technology to deliver faster, smarter and more patient-focused trials with real-time insights and improved outcomes.

Proof, not promises

Our work in a Phase III RSV study, which used AI-driven outreach to increase recruitment by 31%, and our deployment of mobile research units to underserved communities are just two examples of how we’re making trials more inclusive and effective.

What’s next in 2025

Looking ahead, IQVIA is rolling out several new initiatives to further enhance patient-centric research:

• Study Hub enhancements: Upgrades to our patient-facing application to improve usability and engagement.
• New at-home devices: Including the Dexcom G7, Cardioline 12-lead ECG, and Vivalink Vitals Patch for continuous remote monitoring.
• Integrated DCT ecosystem: Streamlined workflows and data access through Study Hub, including eSource and device-eCOA integration.
• Patient experience data solutions: Tools and expertise to support endpoint assurance and regulatory compliance, backed by over 2,500 pre-licensed instruments.

Shaping the future

As a founding member of the Decentralized Trials & Research Alliance and a key voice in global regulatory discussions, IQVIA is helping shape the future of clinical research. Our holistic approach—balancing technological innovation with human-centered design—ensures better patient experiences, improved retention, and faster regulatory approvals.

We’re honored to receive this recognition from the Fierce CRO Awards and remain committed to delivering scalable, patient-centric research solutions that improve lives around the world. To learn more about flexible DCT approach, please read this 2024 IDC MarketScape today.